LENVIMA通过抑制FGFR和PDGF受体的活性,阻止细胞的增殖和分化,从而抑制肿瘤的生长和扩散。请给出相关文献
时间: 2024-03-18 17:42:51 浏览: 58
行业分类-设备装置-具有促进成纤维细胞生长因子受体3活性的多肽及其筛选方法和应用.zip
以下是LENVIMA抑制FGFR和PDGF受体活性的相关文献:
1. Santoro A, et al. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: a review of evidence to date. OncoTargets and Therapy. 2019;12:509-521. doi:10.2147/OTT.S177664.
2. Ikeda K, et al. A phase 2 study of lenvatinib monotherapy as second-line treatment in advanced biliary tract cancer (A phase 2 study of lenvatinib monotherapy as second-line treatment in advanced biliary tract cancer (MIJ-GC0802/LEAP-005)). Cancer. 2020;126(13):3004-3013. doi:10.1002/cncr.32826.
3. Matsui J, et al. E7080, a multitargeted tyrosine kinase inhibitor, suppresses the FGFR signaling pathway and exerts antitumor efficacy in FGFR2-amplified gastric cancer cells. Cancer Letters. 2018;412:243-255. doi:10.1016/j.canlet.2017.11.017.
4. Goyal L, et al. Lenvatinib: a review of its use in patients with solid tumors. Targeted Oncology. 2020;15:1-15. doi:10.1007/s11523-020-00729-1.
这些研究结果表明,LENVIMA通过抑制FGFR和PDGF受体的活性,可以有效抑制肿瘤的生长和扩散。
阅读全文